PRME vs RVTY · rev $4.6M vs P/E 42, rev $1.44B
Prime Medicine, Inc. Common Stock (PRME) versus Revvity Inc. (RVTY) — a side-by-side from cached financials, not a winner call.
Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.
Revvity Inc. (RVTY) is a diagnostics & research company listed on US.
Latest reported PRME revenue for 2025-12-31 was $4.6M. Net income was -$201.1M. Revenue was up 55.3% from 2024-12-31 to 2025-12-31. PRME currently screens at market cap $570.8M.
Latest reported RVTY revenue for 2026-07-05 was $1.44B. Net income was $92.5M. RVTY currently screens at market cap $11.94B and trailing P/E 41.9.
PRME currently screens at market cap $570.8M. RVTY currently screens at market cap $11.94B and trailing P/E 41.9.
Not investment advice. Open the PRME and RVTY stock pages for the full models.
Not investment advice.